Sesen Bio, Inc. is a clinical-stage biotechnology company that is focused on developing fusion protein therapeutics to treat cancer patients. The lead program of the company is known as Vicinium and is presently in a Phase 3 registration trial for non-muscle invasive bladder cancer. Vicinium employs an anti-EpCAM antibody fragment that is attached to a truncated form of Pseudomonas Exotoxin A to target high-risk NMIBC. The company has initiated the BLA submission process for Vicinium to the FDA under Rolling Review.